Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

NCT05371496 on ClinicalTrials.gov · last registry update 2026-08-14

Finished 17 July 2026, after enrolling 81 people. Primary outcome, as filed: Pulmonary Capillary Wedge Pressure (PCWP). semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 81
Started: 2022-09-06
Primary completion: 2026-07-17 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Pulmonary Capillary Wedge Pressure (PCWP)

Conditions studied

Cardiomyopathy · Heart Failure With Preserved Ejection Fraction (HFpEF) · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.